Alectinib composition

Abstract

The invention relates to an alectinib oral drug, and belongs to the technical field of pharmaceutic preparations. The alectinib composition, in every thousand unit doses, contains 150 g of alectinib with D90 being 36-55 micrometers, 4-8 g of tween 80, 8-26 g of fumed silica, 2-8 g of calcium sulfate, 18-32 g of hydroxy propyl celluloses, 20-46 g of lactose anhydrous, 4-8 g of ethylenediamine tetraacetic acid disodium salt and 1.0-1.5 g of magnesium stearate. According to the technical scheme, by reasonable combination of the several components, firstly, dissolution of a main drug is improved,and secondly, by combination effects of the fumed silica, the calcium sulfate and the ethylenediamine tetraacetic acid disodium salt, the moisture resisting and absorption performance in a storage process is improved.

Description

technical field [0001] The invention relates to an alectinib oral medicine, which belongs to the technical field of pharmaceutical preparations. Background technique [0002] Lung cancer is one of the most common malignant tumors in the world, and it has become the first cause of death from malignant tumors in urban population in my country. Non-small cell lung cancer includes squamous cell carcinoma (squamous cell carcinoma), adenocarcinoma, and large cell carcinoma. Compared with small cell carcinoma, its cancer cells grow and divide more slowly, and spread and metastasize relatively later. Non-small cell lung cancer accounts for about 80% of all lung cancers, and about 75% of the patients are found in the middle and advanced stages, and the 5-year survival rate is very low. [0003] Alectinib (also known as alectinib, alectinib,) is FDA-approved for the first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). The drug was develop...

Images